Lysosome-targeting chimaeras for degradation of extracellular proteins.

ABSTRACT: The majority of therapies that target individual proteins rely on specific activity-modulating interactions with the target protein-for example, enzyme inhibition or ligand blocking. However, several major classes of therapeutically relevant proteins have unknown or inaccessible activity profiles and so cannot be targeted by such strategies. Protein-degradation platforms such as proteolysis-targeting chimaeras (PROTACs)^1,2 and others (for example, dTAGs³, Trim-Away⁴, chaperone-mediated autophagy targeting⁵ and SNIPERs⁶) have been developed for proteins that are typically difficult to target; however, these methods involve the manipulation of intracellular protein degradation machinery and are therefore fundamentally limited to proteins

SUBMITTER: Banik SM 

PROVIDER: S-EPMC7727926 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature